سعر بيدريمين 100مجم 30 قرص 2024

Desvenlafaxine 100 mg extended-release tablets, pack of 30 (3 strips); SNRI antidepressant (Mash Premiere, Egypt).

• Major depressive disorder (MDD)Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common (>=5% and twice placebo at 50 or 100 mg): nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety and male sexual function disorders.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Other common reactions in trials: dry mouth, vomiting, fatigue, tremor, abnormal dreams, blurred vision, mydriasis, blood pressure increased; orthostatic hypotension more frequent in patients >=65 years.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity to desvenlafaxine succinate, venlafaxine hydrochloride or any excipient (angioedema has been reported).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Use of MAOIs intended to treat psychiatric disorders with desvenlafaxine or within 7 days of stopping it, or starting desvenlafaxine within 14 days of stopping such an MAOI (serotonin syndrome risk).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Starting desvenlafaxine in a patient being treated with linezolid or intravenous methylene blue.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: antidepressants increased the risk of suicidal thoughts and behaviours in children, adolescents and young adults; monitor all patients closely for clinical worsening and emergence of suicidality, especially early in treatment and at dose changes.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Serotonin syndrome, especially with other serotonergic drugs; discontinue and treat supportively if it occurs.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Elevated blood pressure: control pre-existing hypertension before starting and monitor blood pressure regularly; consider dose reduction or discontinuation for sustained increases.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Monoamine oxidase inhibitors (e.g., selegiline, tranylcypromine, phenelzine, linezolid, methylene blue)Increased risk of serotonin syndrome; concomitant use contraindicated (see timing rules).DailyMed (U.S. National Library of Medicine)
• Other serotonergic drugs (SSRIs, SNRIs, triptans, tricyclics, opioids, lithium, buspirone, amphetamines, tryptophan, St John's wort)Increased risk of serotonin syndrome; monitor and discontinue if it occurs.DailyMed (U.S. National Library of Medicine)
• Drugs that interfere with hemostasis (NSAIDs, aspirin, warfarin)May potentiate bleeding risk; monitor closely for bleeding when desvenlafaxine is started or stopped.DailyMed (U.S. National Library of Medicine)

• No published studies of desvenlafaxine in pregnant women; epidemiologic studies of venlafaxine have not shown a clear association with adverse developmental outcomes. Animal studies showed no teratogenicity, but fetotoxicity and pup deaths occurred in rats at 4.5 times the human exposure. Risks of untreated depression should be considered. SNRI exposure in the month before delivery is associated with a less than 2-fold increased risk of postpartum hemorrhage.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Limited data show low levels of desvenlafaxine in human milk (mean relative infant dose 6.8%) without adverse reactions in breastfed infants; weigh benefits of breastfeeding against maternal need and potential infant effects.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Desvenlafaxine: Potent and selective inhibitor of serotonin and norepinephrine reuptake in the CNS (major active metabolite of venlafaxine); lacks significant affinity for muscarinic, H1 or alpha1 receptors and has no MAO-inhibitory activity.